Your browser doesn't support javascript.
loading
SIRT2: tumour suppressor or tumour promoter in operable breast cancer?
McGlynn, Liane M; Zino, Samer; MacDonald, Alasdair I; Curle, Jennifer; Reilly, Justice E; Mohammed, Zahra M A; McMillan, Donald C; Mallon, Elizabeth; Payne, Anthony P; Edwards, Joanne; Shiels, Paul G.
Afiliación
  • McGlynn LM; Institute of Cancer Sciences, University of Glasgow, Glasgow G11 6NT, UK.
  • Zino S; Institute of Cancer Sciences, University of Glasgow, Glasgow G11 6NT, UK.
  • MacDonald AI; Institute of Cancer Sciences, University of Glasgow, Glasgow G11 6NT, UK.
  • Curle J; Institute of Cancer Sciences, University of Glasgow, Glasgow G11 6NT, UK.
  • Reilly JE; Institute of Cancer Sciences, University of Glasgow, Glasgow G11 6NT, UK.
  • Mohammed ZM; Institute of Cancer Sciences, University of Glasgow, Glasgow G11 6NT, UK.
  • McMillan DC; School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow G4 0SF, UK.
  • Mallon E; School of Medicine, Department of Pathology, University of Glasgow, Southern General Hospital, Glasgow G51 4TF, UK.
  • Payne AP; School of Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.
  • Edwards J; Institute of Cancer Sciences, University of Glasgow, Glasgow G11 6NT, UK.
  • Shiels PG; Institute of Cancer Sciences, University of Glasgow, Glasgow G11 6NT, UK. Electronic address: paul.shiels@glasgow.ac.uk.
Eur J Cancer ; 50(2): 290-301, 2014 Jan.
Article en En | MEDLINE | ID: mdl-24183459
PURPOSE: Sirtuins comprise a family of genes involved in cellular stress, survival and damage responses. They have been implicated in a range of diseases including cancer, with most information pertaining to their function in tumourigenesis being derived from in vitro studies, or model organisms. Their putative roles as tumour suppressors or tumour promoters remain to be validated in vivo. Little is known about their role in breast tumourigenesis. We sought to evaluate the seven sirtuin family members (SIRT1-7) in a human breast cancer cohort, in relation to clinico-pathological features and outcome of the disease. MATERIALS AND METHODS: Immunohistochemical analysis of SIRT1-7 protein levels was undertaken in 392 oestrogen receptor (ER+ve) and 153 ER-ve breast tumour samples. SIRT1-7 transcriptional levels were assessed in normal (n=25), non-malignant (n=73) and malignant (n=70) breast tissue using Relative Quantitative Real Time PCR. Statistical analyses determined if SIRT1-7 transcription or protein expression was associated with clinical parameters or outcome. RESULTS: In ER-ve tumours, high protein levels of nuclear SIRT2 were associated with reduced time to recurrence and disease-specific death. This association was only observed in Grade 3 tumours. In the ER+ve cohort, high SIRT2 nuclear levels were associated with shorter disease-free survival and time to recurrence whilst on Tamoxifen, in patients with Grade 3 tumours. Conversely, in Grade 2 tumours, high SIRT2 levels were associated with increased time to recurrence. CONCLUSIONS: Our data suggest that SIRT2 is the sirtuin predominantly involved in breast tumourigenesis and prognosis. It indicates that SIRT2 acts as a tumour suppressor or tumour promoter dependent upon breast tumour grade.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mama / Neoplasias de la Mama / Biomarcadores de Tumor / Sirtuina 2 Tipo de estudio: Prognostic_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Eur J Cancer Año: 2014 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mama / Neoplasias de la Mama / Biomarcadores de Tumor / Sirtuina 2 Tipo de estudio: Prognostic_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Eur J Cancer Año: 2014 Tipo del documento: Article Pais de publicación: Reino Unido